LGH447
CLGH447X2102
Phase 1 small_molecule completed
Quick answer
LGH447 for AML and High Risk MDS is a Phase 1 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- AML and High Risk MDS
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed